Royal London Asset Management Ltd. Sells 101,078 Shares of Johnson & Johnson (NYSE:JNJ)

Royal London Asset Management Ltd. cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,595,461 shares of the company’s stock after selling 101,078 shares during the quarter. Royal London Asset Management Ltd. owned about 0.07% of Johnson & Johnson worth $233,193,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Gilbert & Cook Inc. lifted its stake in Johnson & Johnson by 3.3% in the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock worth $1,428,000 after purchasing an additional 288 shares during the last quarter. 9258 Wealth Management LLC grew its position in Johnson & Johnson by 2.1% during the 4th quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock worth $3,454,000 after acquiring an additional 443 shares during the last quarter. Gryphon Financial Partners LLC boosted its stake in shares of Johnson & Johnson by 66.3% during the fourth quarter. Gryphon Financial Partners LLC now owns 14,245 shares of the company’s stock valued at $2,244,000 after purchasing an additional 5,680 shares during the period. Horan Securities Inc. increased its stake in shares of Johnson & Johnson by 5.9% in the fourth quarter. Horan Securities Inc. now owns 4,952 shares of the company’s stock worth $776,000 after buying an additional 274 shares during the period. Finally, Summit Place Financial Advisors LLC boosted its position in Johnson & Johnson by 16.5% during the 4th quarter. Summit Place Financial Advisors LLC now owns 19,268 shares of the company’s stock valued at $3,020,000 after buying an additional 2,729 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.5 %

NYSE:JNJ opened at $164.82 on Thursday. The firm has a market capitalization of $396.67 billion, a price-to-earnings ratio of 10.28, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The business has a fifty day moving average price of $158.79 and a 200-day moving average price of $153.93. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.80 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.01%. Johnson & Johnson’s payout ratio is 30.92%.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. Royal Bank of Canada restated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Finally, Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.